Amniotic products market seen reaching $1.65 billion by 2030

The global amniotic products market is projected to grow from $1.08 billion in 2025 to $1.65 billion by 2030, fueled by regenerative medicine, minimally invasive therapies and rising surgical demand. North America led in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Amniotic products are gaining traction in regenerative medicine because they are designed to support tissue repair, reduce inflammation and speed healing. - The market’s expansion points to broader clinical adoption of biologic treatments in orthopedics, sports medicine and surgical recovery. - Growing use could affect how providers approach non-surgical healing and postoperative care.

What happened: - The amniotic products market is projected to rise from $1.08 billion in 2025 to $1.17 billion in 2026. - The market is forecast to reach $1.65 billion by 2030. - The report projects an 8.7% CAGR from 2025 to 2026 and an 8.9% CAGR through 2030. - The Business Research Company published the forecast in its Amniotic Products Global Market Report 2026. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Amniotic products use components derived from the amniotic membrane and fluid. - The products are used as orthobiologic solutions to support tissue repair and reduce joint inflammation. - Direct application to injury sites is intended to promote tissue regeneration and accelerate healing. - Recent market growth has been driven by greater use of orthobiologic treatments, more sports-related injuries, wider availability of amniotic-derived formulations, expanding minimally invasive options and broader acceptance of biologic healing solutions. - Future growth is expected to come from demand for regenerative orthopedic therapies, alternative pain management approaches, outpatient musculoskeletal treatments, investment in biologic products and clinical evidence supporting effectiveness. - The report highlights growing use of amniotic-based orthobiologics, expansion in sports medicine, wider availability of injectable amniotic suspensions, non-surgical healing methods and deeper integration into regenerative treatment protocols. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - Surgical demand is a major near-term catalyst because amniotic products are increasingly used to support recovery, reduce inflammation and lower postoperative pain. - In June 2024, the American Society of Plastic Surgeons said liposuction was the most performed plastic surgery in the US in 2023, with nearly 350,000 operations, up 7% from 2022. - Hand procedures and maxillofacial operations also increased modestly, adding to procedural volume that can support clinical use of amniotic products. - The forecast suggests the market is moving from niche adoption toward broader mainstream use in musculoskeletal care.

What's next: - Market growth is likely to track adoption in regenerative orthopedic care and sports medicine. - Continued clinical evidence could strengthen use in outpatient settings and non-surgical treatment plans. - Asia-Pacific’s rapid growth may narrow the gap with North America over time. - The full report is available here and a free sample is available here.

The bottom line: - Amniotic products are moving into a faster-growth phase as regenerative therapies, surgical demand and outpatient musculoskeletal care converge.